MedtronicMDT
MDT
About: One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
Employees: 95,000
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
52% more first-time investments, than exits
New positions opened: 181 | Existing positions closed: 119
29% more funds holding in top 10
Funds holding in top 10: 24 [Q2] → 31 (+7) [Q3]
10% more call options, than puts
Call options by funds: $818M | Put options by funds: $741M
9% more capital invested
Capital invested by funds: $88.1B [Q2] → $96B (+$7.92B) [Q3]
2% more funds holding
Funds holding: 1,993 [Q2] → 2,026 (+33) [Q3]
3.92% less ownership
Funds ownership: 85.34% [Q2] → 81.43% (-3.92%) [Q3]
16% less repeat investments, than reductions
Existing positions increased: 742 | Existing positions reduced: 887
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$89
1%
upside
Avg. target
$97
10%
upside
High target
$109
24%
upside
5 analyst ratings
3 positive
60%
2 neutral
40%
0 negative
0%
Truist Securities Richard Newitter 79% 1-year accuracy 33 / 42 met price target | 1%upside $89 | Hold Maintained | 18 Dec 2024 |
Barclays Matt Miksic 67% 1-year accuracy 24 / 36 met price target | 24%upside $109 | Overweight Maintained | 26 Nov 2024 |
Bernstein Lee Hambright 83% 1-year accuracy 5 / 6 met price target | 10%upside $97 | Outperform Maintained | 20 Nov 2024 |
Wells Fargo Larry Biegelsen 63% 1-year accuracy 29 / 46 met price target | 11%upside $98 | Overweight Maintained | 20 Nov 2024 |
Baird David Rescott 83% 1-year accuracy 10 / 12 met price target | 6%upside $93 | Neutral Maintained | 20 Nov 2024 |
Financial journalist opinion
Based on 23 articles about MDT published over the past 30 days
Neutral
Zacks Investment Research
4 days ago
BLS Data Shows Slowdown in Core CPI: Time to Buy MDT Stock Now?
Medtronic's strong liquidity position should allow it to meet its near-term debt obligations.
Positive
Zacks Investment Research
5 days ago
Here's Why Medtronic (MDT) Gained But Lagged the Market Today
Medtronic (MDT) concluded the recent trading session at $85.40, signifying a +0.18% move from its prior day's close.
Neutral
Seeking Alpha
1 week ago
Medtronic plc (MDT) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Medtronic plc (NYSE:MDT ) 43rd Annual J.P. Morgan Healthcare Conference Call January 13, 2025 5:15 PM ET Company Participants Geoff Martha - Chief Executive Officer Sean Salmon - EVP & President, Cardiovascular Portfolio Gary Corona - Interim Chief Financial Officer Que Dallara - EVP & President, Diabetes Operating Unit Conference Call Participants Robbie Marcus - JPMorgan Robbie Marcus Good afternoon, everyone.
Neutral
PRNewsWire
1 week ago
Medtronic announces CMS national coverage analysis for Symplicity™ Spyral Renal Denervation System
National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure Milestone is supported by large public health need and robust, long-term data from the SPYRAL-HTN global clinical program GALWAY, Ireland , Jan. 13, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension. This national coverage analysis was initiated by CMS in response to Medtronic's request to support Medicare beneficiary access to the Symplicity™ Spyral renal denervation (RDN) system, used in the Symplicity blood pressure procedure.
Neutral
PRNewsWire
1 week ago
Medtronic achieves CE Mark approval for BrainSense™ Adaptive deep brain stimulation and Electrode Identifier, a groundbreaking advance in personalized, sensing-enabled care for people with Parkinson's through innovative brain-computer interface technology
European approval introduces the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation for people with Parkinson's disease GALWAY, Ireland , Jan. 13, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, announced today CE (Conformité Européenne) Mark approval in the European Union (EU) and the United Kingdom (UK) for BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI), having achieved the standards required by the EU Medical Device Regulation (MDR). In addition, the first programming was completed today, performed by Martijn Beudel, MD, PhD, neurologist and associate professor, Department of Neurology, Amsterdam University Medical Center.
Positive
The Motley Fool
1 week ago
3 Incredible Dividend Stocks to Buy in 2025
There might not be a better place to find winning stocks that can slowly make you wealthy over decades than the healthcare industry. It's an evergreen, multitrillion-dollar market that promotes growth and innovation because better healthcare saves lives.
Positive
The Motley Fool
1 week ago
2 MedTech Stocks That Are Screaming Buys in January
At the intersection of healthcare and technology, medtech companies are leveraging innovative solutions to improve patient care and health outcomes. Industry leaders are well-positioned to deliver shareholder value by addressing the growing healthcare demands of an aging global population and the rising prevalence of chronic diseases.
Positive
The Motley Fool
1 week ago
Is Medtronic's Dividend Safe?
For not just years but decades, Medtronic (MDT 0.04%) has proven to be a reliable dividend growth stock to own. The medical device maker has been increasing its payout regularly, and with a yield of more than 3%, it pays more than twice what the S&P 500 averages (1.3%).
Positive
The Motley Fool
1 week ago
1 Growth Stock Down 6% to Buy Right Now
You can break the stock market into different components, such as investing styles. These are growth and value stocks.
Positive
Seeking Alpha
1 week ago
Medtronic: Scoop Up This Dividend Aristocrat On Sale Now
Shares of Medtronic have lagged the S&P 500 index in the months since my previous article. The company's revenue and non-GAAP EPS grew during its fiscal Q2. Medtronic boasts an A credit rating from S&P on a stable outlook.
Charts implemented using Lightweight Charts™